Evaluation of botulinum toxin type A by bioassays and a validated reversed-phase liquid chromatography method. Issue 3 (21st December 2015)

• Record Type: Journal Article
• Authors: de Freitas, G. W.; Perobelli, R. F.; Maldaner, F. P. S.; Xavier, B.; Dalmora, D. A.; Schramm, V. G.; Dalmora, S. L.
• Is Part Of: Analytical methods. Volume 8:Issue 3(2016)
• Page Start: 587
• Page End: 592
• Publication Date: 2015-12-21
• Subjects: Chemistry, Analytic -- Periodicals; Analytical biochemistry -- Periodicals; Chemical laboratories -- Standards -- Periodicals; 543.1905
• DOI: 10.1039/c5ay02283e
• Languages: English
• ISSNs: 1759-9660

Abstract

Abstract : The biological potency of botulinum toxin type A (BoNTA) in biotechnology-derived products was assessed by the mouse LD50 bioassay (MBA) and the T47D cell culture assay. Abstract : The biological potency of botulinum toxin type A (BoNTA) in biotechnology-derived products was assessed by the mouse LD50 bioassay (MBA) and the T47D cell culture assay. A stability-indicating reversed-phase liquid chromatography (RP-LC) method was validated to determine the content of BoNTA. The method was carried out on a Zorbax 300SB-C18 column (150 mm × 4.6 mm i.d.) maintained at 45 °C. The mobile phase consisted of 0.05 M sodium phosphate buffer solution, pH 2.8, and acetonitrile, run isocratically at a flow rate of 0.3 mL min −1, and using photodiode array (PDA) detection at 214 nm. Separation was obtained with a retention time of 11.4 min, and was linear over the concentration range of 0.2–100 U mL −1 ( r 2 = 0.9999). Specificity was established in degradation studies, which also showed that there was no interference from the excipients. The accuracy was 100.31% with bias lower than 0.80%. The method was applied to the content assessment, and the results were compared to those of the MBA, giving mean values of 1.16% lower, demonstrating potential to improve the characterization and quality consistency of the products.